Small molecule · Inhibitor of integrin alpha-V beta-1 and integrin alpha-V beta-8 · developed by Pliant Therapeutics
PLN-101095 is an orally bioavailable small molecule that dually inhibits integrins alpha-V beta-1 and alpha-V beta-8 in the tumor microenvironment. By blocking these integrins it prevents activation of TGF-beta, which is studied in advanced or metastatic solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06270706 | Phase 1 | Advanced or Metastatic Solid Tumor | Recruiting | PLRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid Tumor
See PLRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PLRX catalysts and pipeline →